EC approves  subcutaneous route of administration in Sandoz biosimilar, Binocrit

EC approves subcutaneous route of administration in Sandoz biosimilar, Binocrit

novartis_logo
Sandoz, a Novartis division and the global leader in biosimilars, announced today that the European Commission (EC) has approved a type II variation for the addition of a subcutaneous (s.c.) route of administration in its drug Binocrit (epoetin alfa), a prescription medicine that stimulates the bone marrow to produce red blood cells (anemia in either the nephrology or oncology setting).
“By expanding our biosimilar offering to the healthcare community, the EC approval of a subcutaneous route of administration for use in our Binocrit’s nephrology indication will mean more choice for healthcare professionals as well as increased convenience for patients” said Carol Lynch, Global Head Biopharmaceuticals, Sandoz.
The EU approval was based on data from the SENSE clinical study – an open label, single arm, multicenter study to evaluate the safety and immunogenicity of HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in pre-dialysis and dialysis patients.
The company says it is committed to increasing patient access to high-quality, life-enhancing biosimilars

About author

You might also like

Philips introduces new diagnostic device to prevent childhood pneumonia

Royal Philips has announced the upcoming release of a Children’s Automated Respiration Monitor, aimed to help improve the diagnosis and treatment of pneumonia in low-resource countries, potentially preventing many of

PHARMA NEWS 0 Comments

Bayer introduces OTC back pain device

German multinational pharmaeuutical company has a drug-free, device for fhe management of pain. The device, Aleve Direct Therapy, uses transcutaneous electrical nerve stimulation (TENS), which delivers stimulating pulses to the

DIABETES PORTAL 0 Comments

Sanofi Diabetes Summit debuts on October 18

All is now set for the first Sanofi Diabetes Forum scheduled to hold in Lagos on Wednesday, October 18, General Manager and Country Chair, Sanofi Nigeria-Ghana, Folake Odediran announced earlier

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply